SATELLOS Retains BND Projects Inc. for Strategic Investor Relations Services
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Toronto,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
Toronto, Ontario -- (August 30, 2021) Satellos Therapeutics Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics
SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug Target TORONTO, ONTARIO –August 26,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
TORONTO, ONTARIO –August 18, 2021, Satellos Bioscience Inc. (“Satellos”) (TSX-V:MSCL), formerly iCo Therapeutics, Inc., and
Satellos and iCo Announce Completion of Reverse Takeover Toronto, Ontario--(Newsfile Corp. - August 13, 2021)
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo